1 of 1
Story summary
- Gilead Sciences said its experimental ulcerative colitis drug emvistegrast met the Phase 2 primary endpoint.
- In the SWIFT trial, 66% of patients receiving 200 mg achieved clinical response versus 37% on placebo.
- Clinical remission occurred in 31% of the 200 mg group compared with 8% for placebo.
- Gilead plans to start a Phase 3 ulcerative colitis study next year and a Phase 2b/3 Crohn’s trial.
- Q2 2026, Gilead reported $7,803 million revenue and a $10,496 million net loss.
